Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Steroid Biochem Mol Biol ; 165(Pt A): 121-123, 2017 01.
Artigo em Inglês | MEDLINE | ID: mdl-27378492

RESUMO

Congenital adrenal hyperplasia (CAH) owing to 21-hydroxylase deficiency is an autosomal recessive disorder caused by mutations in the CYP21A2 gene. Females affected with classical CAH are at risk for genital ambiguity, but can be treated in utero with dexamethasone before 9 gestational weeks to prevent virilization. Early genetic diagnosis is unavailable through current invasive methods of chorionic villus sampling and amniocentesis. New developments in prenatal genetic testing utilize fetal DNA extracted from maternal blood through noninvasive methods, which allow the determination of fetal gender and the diagnosis of CAH at an early gestational age (<9 weeks). Noninvasive prenatal diagnosis allows for the establishment of early and effective management plans in fetuses at risk for CAH and avoids unnecessary prenatal dexamethasone treatment.


Assuntos
Hiperplasia Suprarrenal Congênita/diagnóstico , Hiperplasia Suprarrenal Congênita/genética , Diagnóstico Pré-Natal/métodos , DNA/análise , DNA/sangue , Dexametasona/uso terapêutico , Feminino , Genes Recessivos , Idade Gestacional , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Masculino , Mutação , Gravidez , Virilismo/prevenção & controle
2.
Ann N Y Acad Sci ; 1364: 5-10, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26291314

RESUMO

Congenital adrenal hyperplasia (CAH) owing to 21-hydroxylase deficiency is caused by the autosomal recessive inheritance of mutations in the gene CYP21A2. CYP21A2 mutations lead to variable impairment of the 21-hydroxylase enzyme, which, in turn, is associated with three clinical phenotypes, namely, salt wasting, simple virilizing, and nonclassical CAH. However, it is known that a given mutation can associate with different clinical phenotypes, resulting in a high rate of genotype-phenotype nonconcordance. We aimed to study the genotype-phenotype nonconcordance in a family with three siblings affected with nonclassical CAH. All had hormonal evidence of nonclassical CAH, but this phenotype could not be explained by the genotype obtained from commercial CYP21A2 genetic testing, which revealed heterozygosity for the maternal 30 kb deletion mutation. We performed Sanger sequencing of the entire CYP21A2 gene in this family to search for a rare mutation that was not covered by commercial testing and found in the three siblings a second, rare c.1097G>A (p.R366H) mutation in exon 8. Computational modeling confirmed that this was a mild mutation consistent with nonclassical CAH. We recommend that sequencing of entire genes for rare mutations should be carried out when genotype-phenotype nonconcordance is observed in patients with autosomal recessive monogenic disorders, including CAH.


Assuntos
Hiperplasia Suprarrenal Congênita/genética , Éxons , Deleção de Genes , Heterozigoto , Modelos Moleculares , Mutação Puntual , Esteroide 21-Hidroxilase/genética , Glândulas Suprarrenais/efeitos dos fármacos , Glândulas Suprarrenais/metabolismo , Glândulas Suprarrenais/fisiopatologia , Hiperplasia Suprarrenal Congênita/tratamento farmacológico , Hiperplasia Suprarrenal Congênita/metabolismo , Hiperplasia Suprarrenal Congênita/fisiopatologia , Substituição de Aminoácidos , Inibidores da Aromatase/uso terapêutico , Criança , Biologia Computacional , Análise Mutacional de DNA , Quimioterapia Combinada , Sistemas Inteligentes , Glucocorticoides/uso terapêutico , Humanos , Masculino , Linhagem , Conformação Proteica , Irmãos , Esteroide 21-Hidroxilase/química , Esteroide 21-Hidroxilase/metabolismo , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA